Pazopanib HCl (GW786034 HCl)

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pazopanib HCl (GW786034 HCl) Chemical Structure

Pazopanib HCl (GW786034 HCl) Chemical Structure
Molecular Weight: 473.98

Validation & Quality Control

Customer Reviews(2)

Quality Control & MSDS

Related Compound Libraries

Pazopanib HCl (GW786034 HCl) is available in the following compound libraries:

VEGFR inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Inhibitors
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.







10 nM

30 nM

47 nM

84 nM

74 nM [1]

In vitro Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]
Features A multi-kinase inhibitor.

Protocol(Only for Reference)

Kinase Assay:


Kinase enzyme assays VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.

Cell Assay:


Cell lines HUVEC cells
Concentrations 0-10 μM
Incubation Time 1 hour

Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.

Animal Study:


Animal Models Immunodeficient mice bearing SYO-1 cells
Dosages 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
Administration Oral administration
Solubility 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL


Clinical Trial Information( data from

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT01684397 Recruiting Clear Cell Renal Cell Carcinoma|Stage IV Renal Cell Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI)|GlaxoSmithKline 2012-10 Phase 1|Phase 2
NCT01713972 Recruiting Unspecified Adult Solid Tumor, Protocol Specific Ohio State University Comprehensive Cancer Center|Manisha Shah|National Comprehensive Cancer Network 2012-11 Phase 1
NCT01767636 Recruiting Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma Mayo Clinic 2013-05 Phase 2
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine 2013-05 Phase 1
NCT01841736 Recruiting Metastatic Gastrointestinal Carcinoid Tumor|Pulmonary Carcinoid Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Neuroendocrine Carcinoma of the Skin|Regional Gastrointestinal Carcinoid Tumo National Cancer Institute (NCI) 2013-06 Phase 2

Chemical Information

Download Pazopanib HCl (GW786034 HCl) SDF
Molecular Weight (MW) 473.98


CAS No. 635702-64-6
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms GW786034
Solubility (25°C) * In vitro DMSO 17 mg/mL (35 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.47398 4.7398 9.4796 14.2194

Research Area

Customer Reviews (2)

Click to enlarge
Source J Virol 2011 85, 2296–2303. Pazopanib HCl (GW786034 HCl) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Endothelial cell
Concentrations 0-100 nM
Incubation Time 15-60 min
Results Figure A defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s).The IC50s of pazopanib is 100 nM. we assessed the abilities of VEGFR2 and SFK inhibitors to block ANDV-induced permeability at their IC50s from 15 to 60 min after VEGF addition. The VEGFR2 kinase inhibitor pazopanib inhibited ANDV-induced permeability by 40 to 60% at nanomolar IC50 levels (Figure B).

Click to enlarge
Source J Virol 2011 85, 2296–2303. Pazopanib HCl (GW786034 HCl) purchased from Selleck
Method VE-cadherin internalization
Cell Lines endothelial cell
Concentrations 100 nM
Incubation Time 15 min
Results We found that dasatinib and pazopanib inhibited ANDV-induced VE-cadherin internalization 65 to 70% and resulted in VE-cadherin localization nearly identical to that of mock-infected cells.

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Inhibitors

  • LDK378

    LDK378 is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 2.

    Features:Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

  • AP26113

    AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 1/2.

    Features:At least 10-fold more potent and selective in ALK inhibition relative to crizotinib.

  • CO-1686 (AVL-301)

    CO-1686 is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively. Phase 1/2.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

  • Axitinib

    Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively.

    Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 3.

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

    Features:A multi-kinase inhibitor.

  • Cediranib (AZD2171)

    Cediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3, Phase 2/3.

Recently Viewed Items

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) ic50 | Pazopanib HCl (GW786034 HCl) price | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) solubility dmso | Pazopanib HCl (GW786034 HCl) purchase | Pazopanib HCl (GW786034 HCl) manufacturer | Pazopanib HCl (GW786034 HCl) research buy | Pazopanib HCl (GW786034 HCl) order | Pazopanib HCl (GW786034 HCl) mouse | Pazopanib HCl (GW786034 HCl) chemical structure | Pazopanib HCl (GW786034 HCl) mw | Pazopanib HCl (GW786034 HCl) molecular weight | Pazopanib HCl (GW786034 HCl) datasheet | Pazopanib HCl (GW786034 HCl) supplier | Pazopanib HCl (GW786034 HCl) in vitro | Pazopanib HCl (GW786034 HCl) cell line | Pazopanib HCl (GW786034 HCl) concentration | Pazopanib HCl (GW786034 HCl) nmr
Contact Us